GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Medipal Holdings Corp (OTCPK:MAHLY) » Definitions » Altman Z-Score

MAHLY (Medipal Holdings) Altman Z-Score : 2.73 (As of Dec. 15, 2024)


View and export this data going back to . Start your Free Trial

What is Medipal Holdings Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 2.82 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

Medipal Holdings has a Altman Z-Score of 2.73, indicating it is in Grey Zones. This implies that Medipal Holdings is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Medipal Holdings's Altman Z-Score or its related term are showing as below:

MAHLY' s Altman Z-Score Range Over the Past 10 Years
Min: 2.59   Med: 2.73   Max: 2.91
Current: 2.82

During the past 13 years, Medipal Holdings's highest Altman Z-Score was 2.91. The lowest was 2.59. And the median was 2.73.


Medipal Holdings Altman Z-Score Historical Data

The historical data trend for Medipal Holdings's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medipal Holdings Altman Z-Score Chart

Medipal Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.82 2.73 2.73 2.81 2.89

Medipal Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.79 2.70 2.89 2.91 2.83

Competitive Comparison of Medipal Holdings's Altman Z-Score

For the Medical Distribution subindustry, Medipal Holdings's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medipal Holdings's Altman Z-Score Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Medipal Holdings's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Medipal Holdings's Altman Z-Score falls into.



Medipal Holdings Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Medipal Holdings's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1301+1.4*0.2398+3.3*0.042+0.6*0.4133+1.0*1.8477
=2.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2024:
Total Assets was $13,149 Mil.
Total Current Assets was $9,141 Mil.
Total Current Liabilities was $7,431 Mil.
Retained Earnings was $3,153 Mil.
Pre-Tax Income was 156.743 + 110.015 + 140.276 + 145.053 = $552 Mil.
Interest Expense was -0.014 + -0.006 + -0.013 + -0.014 = $-0 Mil.
Revenue was 6403.144 + 5760.275 + 5632.258 + 6500.321 = $24,296 Mil.
Market Cap (Today) was $3,244 Mil.
Total Liabilities was $7,849 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(9141.423 - 7430.908)/13149.398
=0.1301

X2=Retained Earnings/Total Assets
=3152.602/13149.398
=0.2398

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(552.087 - -0.047)/13149.398
=0.042

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=3244.020/7849.427
=0.4133

X5=Revenue/Total Assets
=24295.998/13149.398
=1.8477

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Medipal Holdings has a Altman Z-Score of 2.73 indicating it is in Grey Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Medipal Holdings  (OTCPK:MAHLY) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Medipal Holdings Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Medipal Holdings's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Medipal Holdings Business Description

Traded in Other Exchanges
Address
2-7-15, Yaesu, Chuo-ku, Tokyo, JPN, 104-8461
Medipal Holdings Corp distributes pharmaceuticals and health and beauty products to medical institutions and retailers. The firm operates in three segments: prescription pharmaceutical wholesale; cosmetics, daily necessities, and OTC pharmaceutical wholesale; and animal health products wholesale. The prescription pharmaceutical business generates the majority of revenue and distributes products to hospitals, clinics, and pharmacies. The cosmetics, daily necessities, and OTC pharmaceutical businesses distribute products to drugstores, convenience stores, and supermarkets. The animal health segment conducts wholesale business for animal hospitals, farms, and agricultural cooperatives. Medipal Holdings generates the vast majority of its revenue in Japan.

Medipal Holdings Headlines

No Headlines